Sequential Infusion of Anti-Cd22 and Anti-Cd19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-All Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature [Corrigendum]

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s255629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Comprehensive Report of Anti-Cd19 Chimeric Antigen Receptor T-Cells (Car-T) Associated Non Relapse Mortality (Cart-Nrm) From Faers

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Anti-Cd19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Third-Generation Anti-Cd19 Chimeric Antigen Receptor T-Cells Incorporating a TLR2 Domain for Relapsed or Refractory B-Cell Lymphoma: A Phase I Clinical Trial Protocol (ENABLE)

BMJ Open
Medicine
2020English

Cytokine Release Syndrome and Neurotoxicity After CD19 Chimeric Antigen Receptor-Modified (CAR-) T Cell Therapy

British Journal of Haematology
Hematology
2018English

Engineering HIV-Resistant, Anti-Hiv Chimeric Antigen Receptor T Cells

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2017English

Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Chimeric Antigen Receptor T-Cells (Car-T) for Refractory and Relapsed Burkitt's Lymphoma: Early Response in Pediatric Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Safety of Allogeneic Hematopoietic Cell Transplant in Adults After Cd19 Targeted Chimeric Antigen Receptor-Modified T-Cell (Car-T) Therapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy